HN1998000036A - Compuesto de pirazina - Google Patents

Compuesto de pirazina

Info

Publication number
HN1998000036A
HN1998000036A HN1998000036A HN1998000036A HN1998000036A HN 1998000036 A HN1998000036 A HN 1998000036A HN 1998000036 A HN1998000036 A HN 1998000036A HN 1998000036 A HN1998000036 A HN 1998000036A HN 1998000036 A HN1998000036 A HN 1998000036A
Authority
HN
Honduras
Prior art keywords
pirazine
compound
homoerithromicina
desofo
aza
Prior art date
Application number
HN1998000036A
Other languages
English (en)
Inventor
Johnson & Johnson Vision Products Inc
Original Assignee
Johnson & Johnson Vision Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704275.8A external-priority patent/GB9704275D0/en
Priority claimed from GBGB9708183.0A external-priority patent/GB9708183D0/en
Application filed by Johnson & Johnson Vision Products Inc filed Critical Johnson & Johnson Vision Products Inc
Publication of HN1998000036A publication Critical patent/HN1998000036A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms

Abstract

LA PRESENTE INVENCION SE REFIERE A DERIVADOS DE 9 DESOFO 9 AZA 9A HOMOERITROMICINA A- C- 4 SUSTITUIDOS.
HN1998000036A 1997-03-01 1998-02-27 Compuesto de pirazina HN1998000036A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9704275.8A GB9704275D0 (en) 1997-03-01 1997-03-01 Pharmacologically active compound
GBGB9708183.0A GB9708183D0 (en) 1997-04-23 1997-04-23 Pharmacologically active compound

Publications (1)

Publication Number Publication Date
HN1998000036A true HN1998000036A (es) 1999-08-23

Family

ID=26311097

Family Applications (2)

Application Number Title Priority Date Filing Date
HN1998000036A HN1998000036A (es) 1997-03-01 1998-02-27 Compuesto de pirazina
HN1999000019A HN1999000019A (es) 1997-03-01 1999-02-11 Granulos homogeneos compuestos por tripolifosfato sodico, sulfato sodico y carbonato sodico procedimiento para su fabricacion y aplicaciones en detergentes y agentes de lavado.

Family Applications After (1)

Application Number Title Priority Date Filing Date
HN1999000019A HN1999000019A (es) 1997-03-01 1999-02-11 Granulos homogeneos compuestos por tripolifosfato sodico, sulfato sodico y carbonato sodico procedimiento para su fabricacion y aplicaciones en detergentes y agentes de lavado.

Country Status (46)

Country Link
US (2) US6255307B1 (es)
EP (1) EP0966448B1 (es)
JP (1) JP3369189B2 (es)
KR (1) KR100544263B1 (es)
CN (1) CN1105111C (es)
AP (1) AP9901632A0 (es)
AR (1) AR011174A1 (es)
AT (1) ATE251143T1 (es)
AU (1) AU732915B2 (es)
BG (1) BG103723A (es)
BR (1) BR9807814B1 (es)
CA (1) CA2282585C (es)
CO (1) CO4950513A1 (es)
CZ (1) CZ295618B6 (es)
DE (1) DE69818643T2 (es)
DK (1) DK0966448T3 (es)
EA (1) EA002102B1 (es)
EE (1) EE9900376A (es)
ES (1) ES2205469T3 (es)
GE (1) GEP20012555B (es)
GT (1) GT199800046A (es)
HK (1) HK1023116A1 (es)
HN (2) HN1998000036A (es)
HR (1) HRP980107A2 (es)
HU (1) HU225852B1 (es)
ID (1) ID22850A (es)
IL (1) IL131293A (es)
IS (1) IS5163A (es)
JO (1) JO2035B1 (es)
MA (1) MA26473A1 (es)
MY (1) MY118612A (es)
NO (1) NO313383B1 (es)
NZ (1) NZ337121A (es)
OA (1) OA11151A (es)
PA (1) PA8448201A1 (es)
PE (1) PE58299A1 (es)
PL (1) PL192864B1 (es)
PT (1) PT966448E (es)
SI (1) SI0966448T1 (es)
SK (1) SK117399A3 (es)
SV (1) SV1998000029A (es)
TR (1) TR199902082T2 (es)
TW (1) TW513416B (es)
UY (1) UY24911A1 (es)
WO (1) WO1998038174A1 (es)
YU (1) YU40799A (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
GB9818881D0 (en) 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
GB9907965D0 (en) * 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
US6479498B1 (en) 1999-06-04 2002-11-12 Theravance, Inc. Sodium channel drugs and uses
EP1500653A1 (en) * 2000-02-16 2005-01-26 Neurogen Corporation Substituted arylpyrazines
HUP0301573A3 (en) * 2000-02-16 2004-03-29 Neurogen Corp Branford Substituted arylpyrazines, pharmaceutical compositions containing them and their use
GB0010971D0 (en) 2000-05-05 2000-06-28 Glaxo Group Ltd Process
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
CA2467870A1 (en) * 2001-11-21 2003-06-05 Pharmacia & Upjohn Company Substituted aryl 1,4-pyrazine derivatives
PT1458386E (pt) * 2001-12-27 2007-06-04 Ortho Mcneil Pharm Inc ''aroilpirrole-heteroarilo e metanóis úteis para o tratamento de um distúrbio do sistema nervoso central''
BR0309551A (pt) 2002-04-26 2005-02-09 Upjohn Co Derivados substituìdos de pirazina
WO2004018437A1 (en) 2002-08-20 2004-03-04 Neurogen Corporation 5-substituted-2-arylpyrazines as modulators of crf receptors
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
AU2004207009A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
TW200510373A (en) * 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
ZA200707125B (en) * 2005-01-25 2008-11-26 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
KR20070104471A (ko) * 2005-02-15 2007-10-25 재즈 파마슈티칼즈 치환된 피라진 화합물의 서방을 위한 투여형 및 그 방법
NL2000284C2 (nl) * 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
WO2007083239A1 (en) * 2006-01-23 2007-07-26 Pfizer Limited Pyridine derivatives as sodium channel modulators
US20100227872A1 (en) * 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
FR3001151B1 (fr) 2013-01-21 2016-04-08 Pf Medicament Association d'un bloqueur de courant sodique lent et d'un inhibiteur du courant if sinusal et les compositions pharmarceutiques la contenant
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
MX2018015625A (es) 2016-06-14 2019-03-06 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN108101857B (zh) * 2016-11-24 2021-09-03 韶远科技（上海)有限公司 制取2-氨基-3-溴-6-氯吡嗪的可放大工艺
CN107011273A (zh) * 2017-05-04 2017-08-04 无锡捷化医药科技有限公司 一种合成6‑碘‑3‑(2,3‑二氯苯基)吡嗪‑2‑胺的方法
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN115611700A (zh) * 2022-10-11 2023-01-17 辽宁东大光明化工科技有限责任公司 一种1-溴-2,5-二氯-3-氟苯的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4402958A (en) * 1981-11-19 1983-09-06 American Cyanamid Company Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates
EP0288431B1 (de) 1987-04-07 1992-08-19 Ciba-Geigy Ag 3H-1,2,3-Triazolo[4,5-d]pyrimidine
JPH08238778A (ja) * 1995-03-07 1996-09-17 Brother Ind Ltd インク噴射装置の電極形成方法

Also Published As

Publication number Publication date
UY24911A1 (es) 2000-12-29
GT199800046A (es) 1999-08-20
PE58299A1 (es) 1999-06-23
US6255307B1 (en) 2001-07-03
BR9807814A (pt) 2000-02-22
EA002102B1 (ru) 2001-12-24
CZ311199A3 (cs) 2000-02-16
NO994213L (no) 1999-10-29
BR9807814B1 (pt) 2009-01-13
AU732915B2 (en) 2001-05-03
US6599905B2 (en) 2003-07-29
ID22850A (id) 1999-12-09
PT966448E (pt) 2004-02-27
EP0966448A1 (en) 1999-12-29
CA2282585C (en) 2006-06-06
YU40799A (sh) 2001-09-28
AR011174A1 (es) 2000-08-02
IL131293A0 (en) 2001-01-28
NO994213D0 (no) 1999-08-31
JO2035B1 (en) 1999-05-15
WO1998038174A1 (en) 1998-09-03
DK0966448T3 (da) 2004-02-02
CZ295618B6 (cs) 2005-09-14
IS5163A (is) 1999-08-24
EP0966448B1 (en) 2003-10-01
CN1105111C (zh) 2003-04-09
SI0966448T1 (en) 2004-04-30
ES2205469T3 (es) 2004-05-01
TR199902082T2 (xx) 2000-04-21
SV1998000029A (es) 1998-12-11
AP9901632A0 (en) 1999-09-30
MY118612A (en) 2004-12-31
PL192864B1 (pl) 2006-12-29
CO4950513A1 (es) 2000-09-01
EA199900687A1 (ru) 2000-04-24
HN1999000019A (es) 1999-08-23
AU6823798A (en) 1998-09-18
PL335441A1 (en) 2000-04-25
EE9900376A (et) 2000-04-17
BG103723A (bg) 2001-05-31
MA26473A1 (fr) 2004-12-20
KR20000075859A (ko) 2000-12-26
PA8448201A1 (es) 2000-05-24
NO313383B1 (no) 2002-09-23
HUP0001802A2 (hu) 2001-05-28
JP2000511203A (ja) 2000-08-29
DE69818643T2 (de) 2004-10-07
JP3369189B2 (ja) 2003-01-20
CA2282585A1 (en) 1998-09-03
HK1023116A1 (en) 2000-09-01
TW513416B (en) 2002-12-11
IL131293A (en) 2003-07-31
DE69818643D1 (de) 2003-11-06
ATE251143T1 (de) 2003-10-15
US20020169172A1 (en) 2002-11-14
KR100544263B1 (ko) 2006-01-23
CN1253551A (zh) 2000-05-17
HRP980107A2 (en) 1998-12-31
NZ337121A (en) 2001-03-30
SK117399A3 (en) 2000-06-12
HU225852B1 (en) 2007-11-28
HUP0001802A3 (en) 2001-07-30
OA11151A (en) 2003-04-22
GEP20012555B (en) 2001-10-25

Similar Documents

Publication Publication Date Title
HN1998000036A (es) Compuesto de pirazina
HN1998000086A (es) Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
HN1998000011A (es) Derivados de acidos arilsulfonilaminohidroxamicos
HN1997000126A (es) Derivados de indazol
HN1997000023A (es) Derivados de lactama
HN1997000146A (es) Derivados de pirimidina biciclica condensada
HN1997000090A (es) Compuestos de piridilpirrol
HN1997000149A (es) Derivados de 6 fenilpiridil 2 amina
HN1999000155A (es) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas
HN1998000020A (es) Derivados de acido arilsulfonilhidroxamico.
HN1999000089A (es) Formulaciones de ziprasidona
HN1998000132A (es) Combinaciones terapeuticas
HN1998000168A (es) Derivados de la tienapirimidina y de la tienapiridina utiles como agentes anticancerigenos.
DK1413582T3 (da) Dimere pyrrolobenzodiazepiner
HN1998000124A (es) Terapia de combinacion
HN1998000030A (es) 2-amino-6-(4fenoxi-2-sustituido)-piridinas sustituidas
HN1998003689A (es) Azetidinas
HN1998000106A (es) Composiciones parenterales de alatroflaxacino
HN1998000028A (es) Otropisomeros de 3 heteroaril - 4 (3h) - quinazolinonas.
HN1998000193A (es) Compuestos de triazina
HN1998000102A (es) Composiciones solubilizadas de sertralina
HN1998000087A (es) Compuestos de amonio cuaternario
UY24327A1 (es) Derivados de cefalosporina
HN1998000165A (es) Polimorfos dofetilina
HN1999000202A (es) Derivados de higromicina